全球药企都在布局 PD-1 plus,思路繁多,到底哪条路才是最正确的?目前并无标准答案,部分跨国药企(MNC)的思考与布局已印证了这一点。例如,作为免疫治疗的开创者,百时美施贵宝(BMS)就向我们展现了 PD-1 plus 探索的多样性。在其探索中,既有证据丰富的成熟组合,也有在现有产品基础上延展的新型联合疗法,还有未来的“制高点行动”。可能这种多样性,恰恰才是 PD-1 plus 的“精髓”:...
Source Link全球药企都在布局 PD-1 plus,思路繁多,到底哪条路才是最正确的?目前并无标准答案,部分跨国药企(MNC)的思考与布局已印证了这一点。例如,作为免疫治疗的开创者,百时美施贵宝(BMS)就向我们展现了 PD-1 plus 探索的多样性。在其探索中,既有证据丰富的成熟组合,也有在现有产品基础上延展的新型联合疗法,还有未来的“制高点行动”。可能这种多样性,恰恰才是 PD-1 plus 的“精髓”:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.